BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Jubilant Pharmova Ltd.’s Q2 FY22 result beat our estimates led by higher revenue from Covid-19 related contract manufacturing organisation deals, which we believe would taper off from Q3 FY22.
Revenue grew 4.2% YoY to Rs 16.6 billion led by recovery in radiopharma and higher CMO sales.
Ebitda margin contracted 150 basis points YoY to 20.5% due to higher selling general and administrative expenses and adjusted profit after tax declined 2.9% YoY to Rs 1.4 billion.
Sartan recall, import alert at Roorkee and pricing pressure in the U.S. market impacted margins.
Jubilant Pharmova's CMO segment recorded incremental revenue from Covid-related deals, which contributed Rs 1.5 billion in Q2 FY22, but would gradually decline going forward with no certainty of continuity.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR